TB Alliance News Update

TB Alliance Welcomes Global Drug Facility’s Listing of Pretomanid

The Stop TB Partnership’s Global Drug Facility (GDF) has added the anti-TB drug pretomanid to its catalog of TB medicines. The “global access price” of US $364 for a six-month treatment course will be available to 150 countries representing the vast majority of the global TB burden.

“We applaud the GDF’s rapid response and view this listing as a significant milestone on the path to ensuring access for those in urgent need,” said Mel Spigelman, President and CEO, TB Alliance, which developed the new treatment option.


Learn more at TBAlliance.org

TB Alliance and Macleods Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB

Non-profit drug developer TB Alliance has granted Macleods Pharmaceuticals Limited a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug “BPaL” regimen.

Learn more at TBAlliance.org

Coming Up on Wednesday, October 30 

Breaking Resistance 

14:30-16:00  |  Avasa Hotel, Constellation Room

TB Alliance and partners will provide an update on treatment for highly drug-resistant forms of tuberculosis.

Featuring remarks from:

• Mel Spigelman, President and CEO, TB Alliance
• Sandeep Juneja, SVP, Market Access, TB Alliance
• Rhea Lobo, TB survivor and Co-Chair, Bolo Didi

Panel discussion including: 

• Lucica Ditiu, Executive Director of Stop TB
• Yogan Pillay, Deputy Director General, Department of Health, South Africa
• Kuldeep Singh Sachdeva, Deputy Director General, Central TB Division Ministry of Health and Family Welfare, Government of India
• Anil Soni, Head of Global Infectious Diseases, Mylan
• Kitty van Weezenbeek, Executive Director, KNCV Tuberculosefonds

We request that those interested in attending please RSVP to the event. Registration opens at 14:00 IST and the event will begin at 14:30, followed by a reception.

https://mailchi.mp/tballiance/tb-alliance-at-the-2019-union-conference-1140273?e=d36444e614